CalciMedica, Inc.

CALC

CIK 0001534133 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$151K
↓-29.4% -$63Kvs FY2024 (Q4)
Gross Profit
$151K
↓-29.4% -$63Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    0ROIC -470.2% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.58 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.04x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -29.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -4012.9% · trend -1118.3pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$28K
investment in PP&E
Stock-based comp (TTM)
$3M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$14M
everything owned
Total liabilities
$20M
everything owed
Stockholders' equity
$-7M
shareholder claim

Recent performance · 29 quarters

Revenue↓-29.4% -$63K
$151K
Net Income↓-38.9% -$2M
$-8M
Free Cash Flow↓-200.0% -$4K
$-6K
Operating Margin↓-1381.7pts
-4012.9%

Drill down